Larry Robbins’ healthcare-heavy hedge fund was able to post much smaller losses than the various health care indices.
Keep Reading →
February 2 - Hedge Funds, Insider Trading - Comments
Maso Capital, an event driven and convertible arbitrage-focused hedge fund based in Hong Kong, was established in 2012 by Manoj Jain and Sohit Khurana, who previously managed ...
Keep Reading →
December 6 - Hedge Funds, Insider Trading - Comments
Soros Fund Management, the family office of billionaire investor and philanthropist George Soros, has recently been confirmed as owning bitcoin by its CEO/CIO Dawn Fitzpatrick...
Keep Reading →
October 12 - Hedge Funds, Insider Trading - Comments
Dividend stocks might look boring, but they can provide exciting returns. Just ask famed activist investor and self-proclaimed Warren Buffett acolyte Bill Ackman.
Keep Reading →
October 8 - Hedge Funds, Insider Trading - Comments
Billionaire crypto investor Mike Novogratz has said bitcoin holding firm at $40,000 during the recent sell-off is a good sign for the market, and recommended buying the dip in...
Keep Reading →
September 23 - Hedge Funds, Insider Trading - Comments
As global hedge funds build their presence in Paris they are poaching from banks on the ground.
Keep Reading →
July 5 - Hedge Funds, Insider Trading - Comments
Activist investor Elliott Management Corp.
Keep Reading →
July 1 - Hedge Funds, Insider Trading - Comments
Brevan Howard Asset Management has stopped accepting new cash into its two biggest multi-manager funds after the firm’s record year of performance swelled the money pools.
Keep Reading →
June 23 - Hedge Funds, Insider Trading - Comments
Billionaire investor Carl Icahn has been a hard-charging shareholder activist for decades.
Keep Reading →
May 26 - Hedge Funds, Insider Trading - Comments
Third Point’s Dan Loeb has two new stakes that are top-ten positions for his hedge fund, according to securities filing.
Keep Reading →
May 17 - Hedge Funds, Insider Trading - Comments
Mike Novogratz, once a partner at Goldman Sachs who went on to be a hedge fund manager at Fortress Investment Group, has found his biggest financial success in cryptocurrency.
Keep Reading →
May 13 - Hedge Funds, Insider Trading - Comments
Dan Kamensky, the hedge-fund founder who pleaded guilty to rigging a bid for shares in Neiman Marcus Group Ltd.’s former Mytheresa subsidiary, is asking a federal judge for ...
Keep Reading →
April 27 - Hedge Funds, Insider Trading - Comments
The retail investing boom is showing signs of slowing down, and short sellers are seizing on the trend as Reddit “meme-stocks” tank.
Keep Reading →
April 16 - Hedge Funds, Insider Trading - Comments
LONDON (Reuters) -Activist hedge fund Elliott Management has taken a multi-billion pound stake in GlaxoSmithKline, the Financial Times reported on Thursday, after a year that ...
Keep Reading →
April 15 - Hedge Funds, Insider Trading - Comments
Crispin Odey’s flagship hedge fund lost money again in 2020, deepening the gloom for the bearish manager as he tries to revive his shrinking firm and fights an indecent assault...
Keep Reading →
January 6 - Hedge Funds, Insider Trading - Comments
Below we present the list of 5 Best Dividend Stocks To Buy According To Billionaire Ken Fisher.
Keep Reading →
November 14 - Dividend Stocks, Hedge Fund Analysis, Hedge Funds, News - Comments
Fisher Investments was founded in 1979 by billionaire Ken Fisher.
Keep Reading →
November 13 - Dividend Stocks, Hedge Funds, News - Comments
NEW YORK (Reuters) - Hedge fund manager Jim Chanos says he is betting that the stocks of physican practice management companies Mednax (MD.N) and Envision Healthcare (EVHC.N) ...
Keep Reading →
July 18 - Hedge Funds, Insider Trading - Comments
GlaxoSmithKline Plc (NYSE:GSK) is forging forward with its cold and flu tracker app even on coming under criticism from skeptics who continue to question the motive behind its...
Keep Reading →
October 19 - News, Stock Analysis - Comments
Back on May 12, 2015, the Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee released a briefing document detailing the process...
Keep Reading →
August 29 - News, Stock Analysis - Comments
To me, flu season is a lot like Christmas; there's a defined time period when we expect it to occur, yet it seems to appear earlier and earlier every year.
Keep Reading →
September 23 - News - Comments
Chemical nerve agents have garnered much media coverage recently, but receiving less attention are the companies involved in the development of countermeasures to these and biological...
Keep Reading →
September 23 - News - Comments
There is perhaps nothing scarier than a cancer diagnosis.
Keep Reading →
September 17 - News - Comments
The small patient pool for medullary thyroid cancer, or MTC, isn't going to move the needle for a large pharmaceutical company. But Exelixis, Inc.
Keep Reading →
September 17 - News - Comments
There's no question that America is addicted to caffeine and sugar.
Keep Reading →
September 17 - News - Comments
GlaxoSmithKline plc (ADR) (NYSE:GSK) and its partner Theravance Inc (NASDAQ:THRX) recently scored a second victory in their quest to treat chronic obstructive pulmonary disease...
Keep Reading →
September 16 - News - Comments
There are plenty of biotech companies that put all of their eggs in one basket these days.
Keep Reading →
September 16 - News - Comments
Looking for the best-performing sector in this year's big market rally? It may just be the biotech sector, which has erupted with astronomical gains in 2013.
Keep Reading →
September 16 - News - Comments
In a way, stocks go through seasons like the weather. Sometimes they spring forth, sometimes they're hot like summer, sometimes they're dormant and cold like winter.
Keep Reading →
September 16 - News - Comments
With the SPDR S&P Biotech Index up 40% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
September 15 - News - Comments
There hasn't been a dull moment for investors of Theravance Inc (NASDAQ:THRX) since the company submitted an NDA for COPD/asthma drug BREO before the Food and Drug Administration...
Keep Reading →
September 12 - News - Comments
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated.
Keep Reading →
September 12 - News - Comments
It hasn't been a fun month to be an investor in clinical-stage biotech ChemoCentryx Inc (NASDAQ:CCXI).
Keep Reading →
September 11 - News - Comments
China has loomed large in health care headlines recently, due to the GlaxoSmithKline plc (ADR) (NYSE:GSK) scandal that erupted in July.
Keep Reading →
September 11 - News - Comments
I know it's like comparing apples and oranges, but humor me for a moment.
Keep Reading →
September 11 - News - Comments
Trading of biopharmaceutical company Theravance Inc (NASDAQ:THRX) was halted on Tuesday. A major decision hung in the balance as the U.S.
Keep Reading →
September 11 - News - Comments
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
September 10 - News - Comments
China's not losing importance in the eyes of investors, despite the world's second-largest economy's slump this year.
Keep Reading →
September 10 - News - Comments
Emerging-market stocks have been butchered over the past few months amid fears that the Federal Reserve will begin winding down its bond-buying program.
Keep Reading →
September 10 - News - Comments
With second-quarter earnings season now in the books and about a month to go before third-quarter earnings kicks off, biotech savvy investors are in for a treat this week with...
Keep Reading →
September 9 - News - Comments
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
September 9 - News - Comments
Over the past decade, the Food and Drug Administration has taken multiple steps to improve the process by which drugs are developed and eventually brought to market.
Keep Reading →
September 4 - News - Comments
ATLANTA (AP) -- When the HPV vaccine was first recommended for boys, health officials worried it would be an unusually hard sell.
Keep Reading →
August 30 - News - Comments
Drugs fail their clinical trials for all kinds of reasons. Sometimes, it's related to efficacy; sometimes, it's safety related.
Keep Reading →
August 30 - News - Comments
In a previous article, I speculated on the race to develop a Duchenne muscular dystrophy, or DMD, drug and who might win it.
Keep Reading →
August 29 - News - Comments
A small section of the total Crohn's Disease) patient population is resistant to standard treatment options.
Keep Reading →
August 29 - News - Comments
ViiV Healthcare -- a joint venture by Pfizer Inc.
Keep Reading →
August 28 - News - Comments
At the same time, the pharmaceutical industry isn't without its share of risks.
Keep Reading →
August 28 - News - Comments
